经导管三尖瓣瓣中瓣及主动脉瓣瓣中瓣植入术
Transcatheter Tricuspid Valve-In-Ring and Aortic Valve-In-Valve Implantation.
作者信息
Reichart Daniel, Schofer Niklas, Deuschl Florian, Schaefer Andreas, Blankenberg Stefan, Reichenspurner Hermann, Schaefer Ulrich, Conradi Lenard
机构信息
Department of Cardiovascular Surgery, Universitätsklinikum Hamburg-Eppendorf, Universitäres Herzzentrum Hamburg GmbH, Hamburg, Germany.
Department of General and Interventional Cardiology, Universitätsklinikum Hamburg-Eppendorf, Universitäres Herzzentrum Hamburg GmbH, Hamburg, Germany.
出版信息
Thorac Cardiovasc Surg Rep. 2017 Jan;6(1):e29-e31. doi: 10.1055/s-0037-1606345. Epub 2017 Sep 18.
Transcatheter heart valve (THV) therapies have shown to be an alternative to surgical valve replacement, especially in high-risk patients requiring redo surgery. However, reports of transcatheter-based interventions in tricuspid valve position are scarce. Here, we report a case of successful concomitant transcatheter aortic valve-in-valve (ViV) and tricuspid valve-in-ring (ViR) procedures using a 23-mm CoreValve Evolut R THV (Medtronic, Inc., Minneapolis, Minnesota, United States) in aortic position and a 29-mm SAPIEN3 (Edwards Lifesciences, Inc., Irvine, California, United States) THV in tricuspid position. This case demonstrates feasibility of concomitant transcatheter aortic ViV and tricuspid ViR procedures.
经导管心脏瓣膜（THV）治疗已被证明是外科瓣膜置换的一种替代方法，特别是在需要再次手术的高危患者中。然而，关于三尖瓣位置基于导管的干预的报道很少。在此，我们报告一例成功同时进行经导管主动脉瓣中瓣（ViV）和三尖瓣环中瓣（ViR）手术的病例，主动脉位置使用23毫米CoreValve Evolut R THV（美敦力公司，明尼阿波利斯，明尼苏达州，美国），三尖瓣位置使用29毫米SAPIEN3（爱德华兹生命科学公司，尔湾，加利福尼亚州，美国）THV。该病例证明了同时进行经导管主动脉ViV和三尖瓣ViR手术的可行性。
Zotero 插件